InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the detailed record of transactions filed by Clayton Russell. Director active across 1 company, notably Larimar Therapeutics, Inc.. Aggregated, 2 filings have been published. History available since 17 January 2024. The latest transaction was filed on 22 January 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
2 of 2 declarations